PhaseBio Pharmaceuticals Inc
OTC:PHASQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Genetic Signatures Ltd
ASX:GSS
|
AU |
|
Xiamen ITG Group Corp Ltd
SSE:600755
|
CN |
|
M
|
Midas Holdings Ltd
SGX:5EN
|
SG |
|
Notorious Pictures SpA
MIL:NPI
|
IT |
|
Crooz Inc
TSE:2138
|
JP |
|
D
|
De Licacy Industrial Co Ltd
TWSE:1464
|
TW |
|
B
|
Blue Zones Holdings Co Ltd
TSE:417A
|
JP |
|
F
|
Fridenson Logistic Services Ltd
TASE:FRDN
|
IL |
|
M
|
Morrow Bank ASA
OSE:MOBA
|
NO |
|
Orient Paper and Industries Ltd
NSE:ORIENTPPR
|
IN |
|
Jaxon Mining Inc
XTSX:JAX
|
CA |
|
S
|
Suzhou Delphi Laser Co Ltd
SSE:688170
|
CN |
|
S
|
Sarawak Consolidated Industries Bhd
KLSE:SCIB
|
MY |
|
Allsec Technologies Ltd
BSE:532633
|
IN |
|
B
|
Beijing Aerospace Changfeng Co Ltd
SSE:600855
|
CN |
|
G
|
GCH Technology Co Ltd
SSE:688625
|
CN |
|
N
|
Nanyang Holdings Ltd
HKEX:212
|
HK |
|
Infore Environment Technology Group Co Ltd
SZSE:000967
|
CN |
|
K
|
King's Town Bank Co Ltd
TWSE:2809
|
TW |
|
Sempio Co
KRX:007540
|
KR |
PhaseBio Pharmaceuticals Inc
EPS (Diluted)
PhaseBio Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PhaseBio Pharmaceuticals Inc
OTC:PHASQ
|
EPS (Diluted)
-$2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
EPS (Diluted)
-$1
|
CAGR 3-Years
32%
|
CAGR 5-Years
27%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
PhaseBio Pharmaceuticals Inc
Glance View
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2018-10-18. The Company’s product pipeline includes Bentracimab (PB2452), PB6440 (for treatment-resistant Hypertension), pemziviptadil (PB1046), GLP2-ELP and CNP-ELP. The firm conducting REVERSE-IT, its pivotal Phase III clinical trial of bentracimab. PB2452 is a novel recombinant human monoclonal antibody antigen-binding fragment, designed to reverse the antiplatelet activity of ticagrelor in the event of major bleeding. PB6440 is an oral selective aldosterone synthase inhibitor for treatment of resistant hypertension. Pemziviptadil (PB1046), is a novel, subcutaneously-injected VIP analogue, which is a recombinant fusion protein composed of VIP and its proprietary ELP technology. ELP technology platform is a growth engine for additional medicines for cardiovascular diseases.
See Also
What is PhaseBio Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-3
USD
Based on the financial report for Dec 31, 2021, PhaseBio Pharmaceuticals Inc's EPS (Diluted) amounts to -3 USD.
What is PhaseBio Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
12%
Over the last year, the EPS (Diluted) growth was 12%.
